Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Meta-Analysis of EGFR Tyrosine Kinase Inhibitors Compared with Chemotherapy as Second-Line Treatment in Pretreated Advanced Non-Small Cell Lung Cancer
Authors
Keywords
-
Journal
PLoS One
Volume 9, Issue 7, Pages e102777
Publisher
Public Library of Science (PLoS)
Online
2014-07-17
DOI
10.1371/journal.pone.0102777
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comparison of the Efficacy and Safety of EFGR Tyrosine Kinase Inhibitor Monotherapy with Standard Second-line Chemotherapy in Previously Treated Advanced Non-small-cell Lung Cancer: a Systematic Review and Meta-analysis
- (2013) Wei-Xiang Qi et al. Asian Pacific Journal of Cancer Prevention
- Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: A Hellenic Oncology Research Group (HORG) randomized phase 3 study
- (2013) Athanasios Karampeazis et al. CANCER
- Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
- (2013) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01)
- (2012) Jong-Mu Sun et al. CANCER
- Beyond first-line NSCLC therapy: chemotherapy or erlotinib?
- (2012) Luis Paz-Ares LANCET ONCOLOGY
- Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
- (2012) Tudor Ciuleanu et al. LANCET ONCOLOGY
- Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer
- (2012) Katsuyuki Hotta et al. LUNG CANCER
- Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
- (2011) Masahiro Fukuoka et al. JOURNAL OF CLINICAL ONCOLOGY
- Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
- (2010) J. C. Soria et al. ANNALS OF ONCOLOGY
- Randomized Phase III Trial of Gefitinib versus Docetaxel in Non-Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy
- (2010) D. H. Lee et al. CLINICAL CANCER RESEARCH
- Randomized, Placebo-Controlled, Phase II Study of Sequential Erlotinib and Chemotherapy As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
- (2009) Tony S.K. Mok et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
- (2008) Riichiroh Maruyama et al. JOURNAL OF CLINICAL ONCOLOGY
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- (2008) Edward S Kim et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started